Crizotinib-induced fatal fulminant liver failure

Lung Cancer

Volumn 93, Issue , 2016, Pages 17-19

  van Geel, Robin M J M ^a   Hendrikx, Jeroen J M A ^a   Vahl, Jelmer E ^b   van Leerdam, Monique E ^a   van den Broek, Daan ^a   Huitema, Alwin D R ^a   Beijnen, Jos H ^a,c   Schellens, Jan H M ^a,c   Burgers, Sjaak A ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b HAGA HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Crizotinib; Fulminant liver failure; Hepatotoxicity; Non small cell lung cancer

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; AMMONIA; BILIRUBIN; CEFOTAXIME; CREATININE; CRIZOTINIB; CYTOCHROME P450 3A; DEXAMETHASONE; GAMMA GLUTAMYLTRANSFERASE; LACTATE DEHYDROGENASE; LACTULOSE; PROTON PUMP INHIBITOR; VANCOMYCIN; VITAMIN K GROUP; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ACUTE LIVER FAILURE; ADULT; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; AMMONIA BLOOD LEVEL; ANTIBIOTIC THERAPY; ARTICLE; BRAIN DISEASE; CARCINOMATOSIS; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG BLOOD LEVEL; ELIMINATION HALF-LIFE; FULMINANT HEPATIC FAILURE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATIC ENCEPHALOPATHY; HEPATORENAL SYNDROME; HUMAN; KIDNEY FUNCTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LEG EDEMA; LIVER FUNCTION; LYMPHANGITIS; MALE; MICTURITION; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SODIUM URINE LEVEL; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICAL AND DRUG INDUCED LIVER INJURY; CHEMICALLY INDUCED; COMPLICATION; FATALITY; FEMALE; LIVER FAILURE, ACUTE; LUNG NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMICAL AND DRUG INDUCED LIVER INJURY; FATAL OUTCOME; FEMALE; HUMANS; LIVER FAILURE, ACUTE; LUNG NEOPLASMS; MIDDLE AGED; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES;

EID: 84959423187     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.12.010     Document Type: Article

References (11)

1. Bray F., Ren J.S., Masuyer E., Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int. J. Cancer 2013, 132:1133-1145. 10.1002/ijc.27711.
2. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566. 10.1038/nature05945.
3. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer-early successes and future challenges. Nat. Rev. Clin. Oncol. 2012, 9:268-277. 10.1038/nrclinonc.2012.43.
4. Shaw A.T., Kim D.-W., Nakagawa K., Seto T., Crinó L., Ahn M.-J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 2013, 368:2385-2394. 10.1056/NEJMoa1214886.
5. FDA, Prescribing information Xalkori® (crizotinib), (2013).
6. O'Grady J.G., Alexander G.J., Hayllar K.M., Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989, 97:439-445.
7. Solomon B.J., Mok T., Kim D.-W., Wu Y.-L., Nakagawa K., Mekhail T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N. Engl. J. Med. 2014, 371:2167-2177. 10.1056/NEJMOA1408440.
8. Camidge D.R., Bang Y., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012, 13:1011-1019. 10.1016/s1470-2045(12)70344-3.
9. Ripault M.-P., Pinzani V., Fayolle V., Pageaux G.-P., Larrey D. Crizotinib-induced acute hepatitis: First case with relapse after reintroduction with reduced dose. Clin. Res. Hepatol. Gastroenterol. 2013, 37:e21-e23. 10.1016/j.clinre.2012.10.003.
10. Sato Y., Fujimoto D., Shibata Y., Seo R., Suginoshita Y., Imai Y., et al. Fulminant Hepatitis Following Crizotinib Administration for ALK-positive Non-small-cell Lung Carcinoma. Jpn. J. Clin. Oncol. 2014, 44:872-875. 10.1093/jjco/hyu086.
11. Spraggs C.F., Budde L.R., Briley L.P., Bing N., Cox C.J., King K.S., et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 2011, 29:667-673. 10.1200/JCO.2010.31.3197.